University of Zimbabwe Institutional Repository

A pilot study to assess the immunologic and virologic efficacy of generic nevirapine, zidovudine and lamivudine in the treatment of HIV-1 infected women with pre-exposure to single dose nevirapine or short course zidovudine and their spouses in Chitungwiza, Zimbabwe

Show simple item record

dc.contributor.author Zijenah, L.S.
dc.contributor.author Kadzirange, G.
dc.contributor.author Rusakanhiko, S.
dc.contributor.author Kufa, T.
dc.contributor.author Gonah, N.
dc.contributor.author Tobaiwa, O.
dc.contributor.author Gwanzura, C.
dc.contributor.author Katzenstein, D. A.
dc.date.accessioned 2016-09-26T09:43:49Z
dc.date.available 2016-09-26T09:43:49Z
dc.date.issued 2006
dc.identifier.citation Zijenah, L. S. et al. (2006). A pilot study to assess the immunologic and virologic efficacy of generic nevirapine, zidovudine and lamivudine in the treatment of HIV-1 infected women with pre-exposure to single dose nevirapine or short course zidovudine and their spouses in Chitungwiza, Zimbabwe. Central African Journal of Medicine, 52 (1/2), 1-8. en_US
dc.identifier.issn 00008-9176
dc.identifier.uri http://hdl.handle.net/10646/2804
dc.description.abstract Objective: A pilot study to assess effectiveness of generic Nevirapine (NVP)+Zidovudine(AZT)+Lamivudine (3TC) as potent antiretroviral therapy (ART) in women exposed to either SD NVP or short course (SC) AZT through participation in prevention of mother-to-child transmission of HIV-1 (pMTCT) interventions, and their spouses. Design: A pilot study of antiretroviral treatment of adults with AIDS. Setting: Primary health care clinics; Seke North and St Mary’s in Chitungwiza, Zimbabwe. Subjects: Women with pre-exposure to SD NVP or SC AZT and their spouses with CD4 count <200 cells/ pL. Interventions: Generic AZT/3TC twice daily plus NVP daily for the first 14 days and then twice a day thereafter, administered to the cohort. Main Outcome Measures: The baseline median CD4 count for women and men was 128.5 and 119.0 cells/ pL respectively. The geomean virus load was similar for the women and men. At weeks 16,24 and 48,82.8%, 85.1% and 73.8% had < 400 copies/ml of HIV RNA respectively. Only at 16 weeks, was the proportion of women (75.9%) with undetectable virus significantly lower than that for men (93.9%). p=0.031. Median CD4 count for both men and women increased significantly, p<0.001. There were no significant differences in virologic responses between the women with pre-exposure to SD NVP and SC AZT. The mean adherence for women and men was similar, >98%. en_US
dc.language.iso en_ZW en_US
dc.publisher University of Zimbabwe, College of Health Sciences en_US
dc.subject Nevirapine en_US
dc.subject pregnant women en_US
dc.subject antiretroviral treatment en_US
dc.subject mother-to-child transmission en_US
dc.title A pilot study to assess the immunologic and virologic efficacy of generic nevirapine, zidovudine and lamivudine in the treatment of HIV-1 infected women with pre-exposure to single dose nevirapine or short course zidovudine and their spouses in Chitungwiza, Zimbabwe en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search UZeScholar


Advanced Search

Browse

My Account

xmlui.statisticsGoogleAnalytics.Navigation.title